SB 169: GENETICS: Provides relative to biomarker testing. (gov sig) (EN NO IMPACT See Note) - Louisiana

SB169 Original → SB169 Act 469 · 2 edits

MINOR

SB 169 was signed into law as Act 469 with one substantive change: the provision that would have defined when clinical utility is 'deemed demonstrated' for biomarker testing (new R.S. 22:1028.5(B)(4)) was removed from the final version. The remaining provisions - requiring coverage to apply to the test itself regardless of lab classification, and resolving conflicts with R.S. 22:1028.3 - were carried through unchanged.

Scope change

The bill's scope narrowed slightly. The original version would have both clarified the clinical utility standard AND prevented lab-classification-based denials. The final act only addresses the lab-classification issue, leaving the existing clinical utility framework untouched.

DEFINITION

The original bill included a new definition stating that clinical utility is 'deemed demonstrated when a biomarker test meets any one of the criteria listed in Paragraph (2) of this Subsection.' This provision (R.S. 22:1028.5(B)(4)) was dropped entirely from the enrolled act, leaving the existing standard for establishing clinical utility unchanged.

SCOPE

The act's stated purpose narrowed from 'to clarify what constitutes clinical utility; to prevent coverage from being nullified through lab classification' to simply 'to prevent coverage from being nullified through lab classification,' reflecting the removal of the clinical utility definition.

SB169 Engrossed → SB169 Enrolled · 3 edits · May 25, 2026

MINOR

The bill moved from Engrossed to Enrolled status, indicating it passed both chambers. The House removed the provision that would have defined how clinical utility is deemed demonstrated for biomarker testing (R.S. 22:1028.5(B)(4)), leaving only the provision protecting coverage from being nullified through laboratory classifications or credentialing standards. A co-sponsor from the House was added.

DEFINITION

The provision defining clinical utility as deemed demonstrated when a biomarker test meets any one of the criteria in Paragraph (2) of Subsection B (R.S. 22:1028.5(B)(4)) was removed. This means the bill no longer establishes a specific legal standard for when clinical utility is considered proven.

SCOPE

The bill's scope narrowed from amending both R.S. 22:1028.5(D) and enacting both (B)(4) and (F), to only amending (D) and enacting (F). The remaining substantive provision still prevents insurers from conditioning coverage on laboratory classifications or credentialing standards unrelated to the test itself.

TECHNICAL

Representative Chassion was added as a co-sponsor, reflecting passage through the House of Representatives.

SB169 Engrossed → SB169 Act 469 · 4 edits

MODERATE

This bill was finalized as Act No. 469, adding a Representative as a co-sponsor and formally enrolling the legislation. The core policy text regarding biomarker testing coverage remains substantively identical to the previous Engrossed version, with no changes to the specific requirements for insurers or the definition of clinical utility.

Scope change

The bill's scope and applicability remain unchanged; the text governing health coverage plans and biomarker testing is identical to the Engrossed version.

TECHNICAL

Added Representative Chassion as a co-sponsor to the bill.

Changed the document title from 'ENGROSSED' to 'ENROLLED' and added Act No. 469, indicating the bill has passed both legislative chambers and the governor's office.

Removed the Senate Legislative Services digest and summary, as these explanatory notes are not included in the final enrolled act.

Adjusted line numbers and formatting to reflect the final enrolled version of the statute.

SB169 Original → SB169 Engrossed · 2 edits · May 19, 2026

MINOR

The bill text has been updated from the original version to the engrossed version, reflecting final approval by the legislature. The substantive policy content regarding biomarker testing coverage remains unchanged, while the document metadata and formatting have been adjusted to indicate the bill is now in its final form.

TECHNICAL

Updated document headers and titles to reflect the bill status as 'Engrossed' instead of 'Original', indicating it has passed all legislative stages.

Changed the digest section title from 'SB 169 Original' to 'SB 169 Engrossed' to match the final version of the bill.

SB169 Enrolled → SB169 Original · 3 edits

MINOR

The bill was renumbered and its text was revised to clarify how clinical utility for biomarker testing is defined and to explicitly prohibit insurance plans from denying coverage based on unrelated laboratory classifications. These changes aim to prevent insurance nullification and ensure consistent coverage for genetic testing across different medical contexts.

Scope change

The bill's scope was expanded to clarify the definition of clinical utility and to resolve inconsistencies between laws governing cancer screening and biomarker testing for existing conditions.

DEFINITION

Added a specific definition for 'clinical utility' to determine when biomarker testing qualifies for coverage.

REQUIREMENT

Revised the requirement that coverage must not be conditioned on laboratory classifications or credentialing standards unrelated to the test's performance.

TECHNICAL

Updated the bill's title, sponsor list, and statutory references to reflect the new text and renumbered sections.

GENETICS: Provides relative to biomarker testing. (gov sig) (EN NO IMPACT See Note)

What changed between versions

How they voted

Actions timeline

Sponsors